Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy

Seung Yoon Park, In-San Kim

Research output: Contribution to journalShort survey

Abstract

Myeloid lineage immune cells, such as macrophages and dendritic cells, play important roles in the induction of antitumor immunity during the initial stage of the cancer-immunity cycle, eliciting antitumor adaptive immunity by phagocytosing cancer cells and processing cancer-specific antigens, and then presenting these antigens to T cells. During this process, cancer cell phagocytosis can be prevented by inhibitory signals, and the signaling cascades that elicit immune responses against cancer antigens can be inhibited by immunosuppressive myeloid cells in the tumor microenvironment. A number of therapeutic strategies for enhancing cancer cell phagocytosis and promoting antitumor immunity by targeting myeloid lineage cells have recently been developed. Here, we discuss recent advances in cancer immunotherapy that involve the targeting of myeloid lineage immune cells to induce effective antitumor immunity.

Original languageEnglish
Pages (from-to)51-58
Number of pages8
JournalCancer letters
Volume452
DOIs
Publication statusPublished - 2019 Jun 28

    Fingerprint

Keywords

  • Antitumer immunity
  • Dendritic cells
  • Macrophages
  • Phagocytosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this